There are currently 40 active clinical trials seeking participants for Carcinoma, Non-Small-Cell Lung research studies. The states with the highest number of trials for Carcinoma, Non-Small-Cell Lung participants are California, Texas, Florida and New York.
A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer
NCT05068024
Recruiting
The purpose of this study is to characterize the safety and tolerability of FWD1509 MsOH in advanced NSCLC patients and establish the maximum tolerable dose (MTD), recommended phase 2 dose (RP2D) in advanced NSCLC patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/20/2022
Locations: Gabrail Cancer Center, Canton, Ohio +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study of Pembrolizumab (MK-3475) With or Without V940 in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422
Recruiting
The goal of this study is to learn if people who receive V940 and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving V940 and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Providence St. Jude Medical Center ( Site 0106), Fullerton, California +45 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors
NCT05983133
Recruiting
This study will test the safety of a drug called PF-08046052/SGN-EGFRd2 in participants with advanced solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. Participants will have cancer that cannot be removed (unresectable) or has spread through the body (metastatic). This study will have three parts. Parts A and B of the study will find out how much PF-08046052/SGN-EGFRd2 should be given to participants.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: UCLA Department of Medicine - Hematology & Oncology, Santa Monica, California +12 locations
Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma
Register for Updates
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
NCT04165070
Recruiting
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naïve participants with advanced squamous or non-squamous NSCLC. This study is one of the pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona +38 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
NCT06140836
Recruiting
The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Local Institution - 0136, Augusta, Georgia +143 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
NCT06623656
Recruiting
The goal of this clinical trial is to learn if Cemiplimab with chemotherapy or Cemiplimab with stereotactic body radiation therapy (SBRT) works as treatment for stages IB, II, and III (N2) Non-Small Cell Lung Cancer (NSCLC). Before surgery to remove their lung cancer, participants will take: 1. Cemiplimab with chemotherapy (Arm A) every 3 weeks for up to 3 doses, OR 2. Cemiplimab every 3 weeks for up to 3 doses with SBRT (Arm B). SBRT will be given on day 1 before taking cemiplimab, then SBRT... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Weill Cornell Medicine, New York, New York
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
NCT06447662
Recruiting
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose. This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that: * are advanced (cancer that doesn't disappear or stay away with treatment) and * have a KRAS gene mutation (a change in the DNA of the KRAS gene that can cause cells to gro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Highlands Oncology Group, Springdale, Arkansas +9 locations
Conditions: Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study of SGN-MesoC2 in Advanced Solid Tumors
NCT06466187
Recruiting
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +18 locations
Conditions: Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial
Register for Updates
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene
NCT06704724
Recruiting
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer. This study also aims to find the best amount of study medication. This study is seeking participants who have solid tumors (a mass of abnormal cells that forms a lump or growth in the body) that: * are advanced (cancer that doesn't disappear or stay away with treatment) a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: City of Hope (City of Hope National Medical Center, City Of Hope Medical Center), Duarte, California +1 locations
Conditions: Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Register for Updates
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT04956640
Recruiting
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +48 locations
Conditions: Carcinoma, Non-Small-Cell Lung, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms, Colorectal Neoplasms
Register for Updates
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06120140
Recruiting
The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (\>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib. A substudy will enroll participants from Arms A and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Ironwood Cancer and Research Center, Chandler, Arizona +92 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT05544929
Recruiting
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/04/2025
Locations: Massachusetts General Hospital ., Boston, Massachusetts +14 locations
Conditions: Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms
Register for Updates